drug
divesiran
Phase 2updated 6mo agoby $SLN Silence Therapeutics plc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
News(10)
- 5 acquisitions that forced Big Pharmas to co-parentAcquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…biospace · 1d ago
- Merck KGaA makes noise in hematology with $1.1B Silence buySilence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.biospace · 1mo ago
- Merck KGaA bets on RNAi with $1.3B Silence buyoutThe acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.biopharma_dive · 1mo ago
- Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3BGermany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using genetic medicines. Silence is developing the s…endpoints · 1mo ago
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer winGermany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.fiercebiotech · 1mo ago
- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…biospace · 2mo ago
- Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesSome analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…biopharma_dive · 3mo ago
- Silence causes uproar in rare blood cancer space as data sets high bar for competitorsThe mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…biospace · 3mo ago
- Silence spells out Phase 2 success for gene-silencing drug in rare blood cancerSilence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said Monday that its drug ...endpoints · 3mo ago
- STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancerA rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.stat · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that